AC Immune (ACIU) Other Non-Current Assets (2014 - 2026)
AC Immune (ACIU) posted quarterly Other Non-Current Assets of $747.0 million for Q1 2026, up 114712.68% year-over-year from N/an in Q1 2025, and up 2.24% quarter-over-quarter from $730.7 million in Q4 2025.
AC Immune (ACIU) Other Non-Current Assets (2014 - 2026) Analysis & Trends
AC Immune (ACIU) has reported Other Non-Current Assets for 13 consecutive years, with $747.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Non-Current Assets rose 114712.68% year-over-year to $747.0 million; the TTM figure through Mar 2026 stood at $747.0 million (up 114712.68% YoY), while the FY2025 annual figure was $704.4 million, up 148587.38% from the prior year.
- Other Non-Current Assets advanced to $747.0 million in Q1 2026 per ACIU's latest filing, from $730.7 million in the prior quarter.
- Across five years, Other Non-Current Assets topped out at $747.0 million in Q1 2026 and bottomed at $373799.8 in Q3 2022.
- Historically, Other Non-Current Assets has averaged $156.4 million across 5 years, with a median of $478996.0 in 2024.
- Annual changes were most pronounced in 2022 — Other Non-Current Assets sank 99.91% — and 2025, when it surged 154139.91%.
- AC Immune's Other Non-Current Assets stood at $374725.9 in 2022, then surged by 108506.04% to $407.0 million in 2023, then plunged by 99.88% to $473731.6 in 2024, then soared by 154139.91% to $730.7 million in 2025, then grew by 2.24% to $747.0 million in 2026.
- Business Quant data shows ACIU's Other Non-Current Assets at $747.0 million in Q1 2026, $730.7 million in Q4 2025, and $730064.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 124.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 42.45 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 109.58 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 18,237.65 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 62.96 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 65.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 104.44 Mn |
| 10 | AC Immune | 253.89 Mn | 253.89 Mn | - | 740,164.87 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 740,164.87 |
| Mar 31, 2026 | 747.05 Mn |
| Dec 31, 2025 | 730.68 Mn |
| Sep 30, 2025 | 730,063.96 |
| Jun 30, 2025 | 705,407.89 |
| Mar 31, 2025 | 650,666.56 |
| Dec 31, 2024 | 473,731.57 |
| Sep 30, 2024 | 478,996.01 |
| Jun 30, 2024 | 458,904.30 |
| Mar 31, 2024 | 475,458.16 |
| Dec 31, 2023 | 406.97 Mn |
| Sep 30, 2023 | 408,707.08 |
| Jun 30, 2023 | 401,495.37 |
| Mar 31, 2023 | 390,299.69 |
| Dec 31, 2022 | 374,725.91 |
| Sep 30, 2022 | 373,799.85 |
| Jun 30, 2022 | 374.82 Mn |
| Mar 31, 2022 | 393.06 Mn |
| Dec 31, 2021 | 393.67 Mn |
| Sep 30, 2021 | 395.35 Mn |